The Effect of Gefitinib Combined with Syndrome Differentiation of Traditional Chinese Medicine on EGFR, BRAF in Patients with Advanced Lung Adenocarcinoma

Hu Gaifeng, Hu Zhao, Yang Jin

Chinese Pharmaceutical Affairs ›› 2020, Vol. 34 ›› Issue (7) : 840-844.

Chinese Pharmaceutical Affairs ›› 2020, Vol. 34 ›› Issue (7) : 840-844. DOI: 10.16153/j.1002-7777.2020.07.018
Clinical Pharmacy

The Effect of Gefitinib Combined with Syndrome Differentiation of Traditional Chinese Medicine on EGFR, BRAF in Patients with Advanced Lung Adenocarcinoma

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2020, 34(7): 840-844 https://doi.org/10.16153/j.1002-7777.2020.07.018

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}

Accesses

Citation

Detail
Sections
Recommended
京ICP备17052540号-4
Copyright © Chinese Pharmaceutical Affairs, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉